All In Biotech

Drug Trial Radar · NCT02723955

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

829

Actual

Start

Jun 23, 2016

Primary completion

Jul 5, 2023

Study completion Jul 5, 2023

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Mar 31, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 93 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab or chemotherapy regimens. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab or GSK3174998 or chemotherapy or pembrolizumab plus chemotherapy or dostarlimab plus cobolimab or Bintrafusp alfa combination dose escalation phase and Part 2B expansion phase with pembrolizumab. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.

Conditions

  • Neoplasms

Interventions

  • feladilimab (GSK3359609)Drug

  • GSK3174998Drug

  • PembrolizumabDrug

  • DocetaxelDrug

  • PemetrexedDrug

  • Paclitaxel plus CarboplatinDrug

  • Gemcitabine plus CarboplatinDrug

  • Fluorouracil (5-FU) plus carboplatin or cisplatinDrug

  • DostarlimabDrug

  • CobolimabDrug

  • Bintrafusp alfaDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)Time frame: Up to approximately 367 weeks
  2. Part 1A: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to 28 days
  3. Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry ParametersTime frame: Baseline (Day 1) and up to approximately 367 weeks
  4. Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to approximately 367 weeks
  5. Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology ParametersTime frame: Baseline (Day 1) and up to approximately 367 weeks
  6. Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to approximately 367 weeks
  7. Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to BaselineTime frame: Up to approximately 367 weeks
  8. Part 1A: Number of Participants With Dose Modifications of FeladilimabTime frame: Up to approximately 367 weeks
  9. Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)Time frame: Up to approximately 367 weeks
  10. Part 2A: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to 28 days
  11. Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry ParametersTime frame: Baseline (Day 1) and up to approximately 367 weeks
  12. Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to approximately 367 weeks
  13. Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology ParametersTime frame: Baseline (Day 1) and up to approximately 367 weeks
  14. Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to approximately 367 weeks
  15. Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to BaselineTime frame: Up to approximately 367 weeks
  16. Part 2A: Number of Participants With Dose Modifications of FeladilimabTime frame: Up to approximately 367 weeks

Locations

28 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Duarte, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Sarasota, Florida

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Oklahoma City, Oklahoma

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Heidelberg, Victoria, Australia

  • GSK Investigational Site

    Melbourne, Victoria, Australia

  • GSK Investigational Site

    Nedlands, Western Australia, Australia

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Shnghai, China

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Villejuif, France

  • GSK Investigational Site

    Siena, Tuscany, Italy

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Amsterdam, Netherlands

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Mága, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.